Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-01 (Varenicline Solution) Nasal Spray in Dry Eye Disease
NCT05514041Phase 4Completed
- Sponsor
- Stephenson Eye Associates
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in dry eye disease (DED) comparing OC-01 (varenicline solution) nasal spray 0.03 mg with Placebo nasal spray (OC-01 Vehicle Nasal Spray) (2 arms). Primary endpoint: Surface qualifier image change at Day 1. Started Oct 2022; status: completed.
02
Drugs
varenicline + nicotine patch
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05514041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514041.